NASH – accelerating awareness, identification and clinical trial enrollment

Sponsored by:

Date: 2 June 2021 (Wednesday)
Time: San Diego – 08:00 | Chicago – 10:00 | New York – 11:00 | London – 16:00 | Paris – 17:00 | Israel – 18:00 | Singapore – 23:00 | Tokyo – 00:00 (3 June 2021)
Duration: 90 minutes
Event structure: 15 min presentation x 3 + 40-min panel discussion
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight 16 June 2021 (registration is required)

Non-alcoholic steatohepatitis (NASH) is a growing health concern that affects millions of patients worldwide. NASH is often a silent disease with limited obvious symptoms at an early stage. Many patients remaining asymptomatic resulting in few patients actively seeking treatment. The public health implications of this disease have driven research and investment toward diagnostics and treatments, but many challenges remain in finding NASH patients for clinical trials. In this webinar, a panel of speakers will explore the challenges to successfully bring effective therapies to market and how we might overcome them.

Presentation Topics :

• Diagnosis of NASH: to biopsy or not to biopsy?
• Challenges in identifying Patients with NASH for Prevention and Treatment
• A Community-based approach to NASH recruitment

Panel Discussion: An expert view on NASH challenges in clinical trials and patient identification

1. Drug pipeline, and dual therapy for NASH
2. Regulatory view of liver biopsy as Gold Standard
3. Place of non-invasive markers in diagnosis of NASH
4. NASH clinical trial endpoint
5. NASH therapy in future
6. Question and Answer session